What investment did MUFG Capital Co., Ltd. make in KOEDA Co., Ltd., and through which fund was it executed?

MUFG Capital Co., Ltd. invested in KOEDA Co., Ltd. via the Mitsubishi UFJ Life Science Fund No. 4 Investment Limited Partnership, which it operates.

Who founded KOEDA Co., Ltd., what is his professional background, and which university collaborated on the research?

KOEDA Co., Ltd. was founded by Dr. Toru Okuzono, a gastroenterologist and endoscopy specialist, in collaboration with the Graduate School of Biomedical Engineering at Tohoku University.

What is the name of the organ‑fixing anchor developed by KOEDA, and for which digestive disease is it initially being tested?

The organ‑fixing anchor is called KOEDA™ and it is initially being developed for the treatment of acute cholecystitis.

What clinical trial stage has KOEDA completed for acute cholecystitis, and what are the next planned trial locations?

KOEDA has finished exploratory clinical trials for acute cholecystitis and is planning confirmatory clinical trials in Japan with future expansion to the United States.

Besides acute cholecystitis, what additional medical application is KOEDA targeting, and in which countries are animal studies currently progressing?

KOEDA is also targeting gastrojejunal bypass surgery, and its animal studies are progressing smoothly in both Japan and Spain.

AI News NQ Analysis

MUFG Capital Invests in KOEDA Co., Ltd., Developing Next-Generation Anchors for Innovative Digestive Disease Treatment

NQ Score 89/100

N1 Content Completeness 90

AI Summary (NQ-processed)

MUFG Capital has invested in KOEDA Co., Ltd., a medical device startup developing next-generation anchors for endoscopic treatment of digestive diseases. KOEDA aims to innovate treatments for acute cholecystitis and gastrojejunal bypass, planning clinical trials and expansion in Japan, the US, and Spain, supported by MUFG's network.

AI Analysis

Frequently Asked Questions

Q: What investment did MUFG Capital Co., Ltd. make in KOEDA Co., Ltd., and through which fund was it executed?: A: MUFG Capital Co., Ltd. invested in KOEDA Co., Ltd. via the Mitsubishi UFJ Life Science Fund No. 4 Investment Limited Partnership, which it operates.
Q: Who founded KOEDA Co., Ltd., what is his professional background, and which university collaborated on the research?: A: KOEDA Co., Ltd. was founded by Dr. Toru Okuzono, a gastroenterologist and endoscopy specialist, in collaboration with the Graduate School of Biomedical Engineering at Tohoku University.
Q: What is the name of the organ‑fixing anchor developed by KOEDA, and for which digestive disease is it initially being tested?: A: The organ‑fixing anchor is called KOEDA™ and it is initially being developed for the treatment of acute cholecystitis.
Q: What clinical trial stage has KOEDA completed for acute cholecystitis, and what are the next planned trial locations?: A: KOEDA has finished exploratory clinical trials for acute cholecystitis and is planning confirmatory clinical trials in Japan with future expansion to the United States.
Q: Besides acute cholecystitis, what additional medical application is KOEDA targeting, and in which countries are animal studies currently progressing?: A: KOEDA is also targeting gastrojejunal bypass surgery, and its animal studies are progressing smoothly in both Japan and Spain.